PERJETA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PERJETA (PERJETA).
Pertuzumab is a humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 (HER2), thereby inhibiting ligand-dependent heterodimerization of HER2 with other HER family members (including EGFR, HER3, and HER4), blocking downstream signaling pathways such as PI3K/AKT and MAPK, and mediating antibody-dependent cell-mediated cytotoxicity (ADCC).
| Metabolism | Pertuzumab is a monoclonal antibody and is expected to be degraded into small peptides and amino acids via general protein catabolic pathways. No specific metabolic enzymes are involved. |
| Excretion | Primarily eliminated via reticuloendothelial system and catabolism; renal excretion minimal (<1% as unchanged drug), biliary/fecal elimination accounts for the majority of clearance via IgG catabolism. |
| Half-life | Terminal elimination half-life approximately 18 days (range 11–23 days) following intravenous administration; supports 3-weekly dosing regimen. |
| Protein binding | 97-99% bound to plasma proteins, primarily to immunoglobulins and albumin. |
| Volume of Distribution | Approximately 2.7 L/kg (range 2.3–3.1 L/kg), indicating extensive distribution into tissues including tumor interstitium. |
| Bioavailability | Not applicable; administered only intravenously with 100% bioavailability. |
| Onset of Action | Clinical effect (inhibition of HER2 signaling) begins within hours of first dose; maximal receptor blockade achieved by steady state (~6 weeks). |
| Duration of Action | Duration of action persists for the dosing interval (3 weeks); sustained HER2 blockade maintained with repeated doses; clinical effect wanes after drug clearance. |
| Action Class | HER2/neu (ErbB2) Inhibitor- Monoclonal antibody |
Loading dose 840 mg IV over 60 minutes, then 420 mg IV over 30–60 minutes every 3 weeks.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Insufficient data for severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Insufficient data for moderate to severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required for patients ≥65 years; use standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PERJETA (PERJETA).
| Breastfeeding | No data on pertuzumab in human milk; M/P ratio unknown. IgG is present in human milk, but absorption is limited. Because of the potential for adverse reactions in the nursing infant, breastfeeding is not recommended during therapy and for 7 months after the last dose. |
| Teratogenic Risk | Pertuzumab is an IgG1 monoclonal antibody; IgG molecules cross the placenta. Based on its mechanism of action (HER2 receptor blockade), it is expected to cause fetal harm. In animal studies, pertuzumab caused oligohydramnios, delayed renal development, and fetal death. Risk is highest during the second and third trimesters as placental transfer increases. First trimester exposure may also pose risk due to potential placental transfer, but data are limited. |
■ FDA Black Box Warning
WARNING: LEFT VENTRICULAR DYSFUNCTION. Pertuzumab can cause subclinical and clinical cardiac failure as manifested by decreased left ventricular ejection fraction (LVEF) and congestive heart failure. Assess LVEF prior to initiation of PERJETA and at regular intervals during treatment. Discontinue PERJETA for a confirmed clinically significant decrease in LVEF.
| Serious Effects |
None known.
| Precautions | ["Left Ventricular Dysfunction: Assess LVEF prior to and during treatment; withhold or discontinue for significant decline.","Infusion-Related Reactions: Monitor for signs and symptoms; interrupt or slow infusion for severe reactions.","Hypersensitivity Reactions: Including anaphylaxis; permanently discontinue for severe reactions.","Embryo-Fetal Toxicity: Can cause fetal harm; advise patients of reproductive potential to use effective contraception during and after treatment.","Pulmonary Toxicity: Severe and fatal pulmonary events (e.g., interstitial lung disease, pneumonitis) have been reported.","Chemotherapy-Induced Neutropenia: Increased incidence of febrile neutropenia when used with myelosuppressive chemotherapy."] |
Loading safety data…
| Fetal Monitoring | Monitor for oligohydramnios if pertuzumab is used during pregnancy; perform ultrasound assessment of amniotic fluid volume at baseline and periodically during treatment. Monitor for signs of HER2 blockade-related fetal toxicity. For pregnant patients, recommend serial fetal assessments including renal function. |
| Fertility Effects | No direct human data on fertility. In animal studies, no adverse effects on male or female reproductive organs were observed. However, based on its mechanism, it may impair fertility (e.g., ovarian failure) due to HER2 expression in reproductive tissues. |